Longitudinal Study of Humoral and Cellular Responses to COVID-19 mRNA Vaccines With and Without 3rd (‘Booster’) Dose in MS Patients on Ocrelizumab▼: 24-week Results From VIOLA (NCT04843774)
Patients with multiple sclerosis (MS) receiving ocrelizumab▼ (OCR) have attenuated antibody but largely intact T-cell responses to the COVID-19 vaccination; however, little is known about the durability of post-vaccine responses in this population. The objective of this study was to examine longitudinal antibody and cellular responses to two-dose mRNA-platform COVID-19 vaccines (Pfizer-BioNTech and Moderna) in OCR▼-treated patients with MS over a 24-week period and to assess the effect of a ‘booster’ (third dose) on antibody and T-cell responses.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.